Soluble CD163 from activated macrophages predicts mortality in acute liver failure

Holger Jon Møller, Henning Grønbæk, Frank V. Schiødt, Peter Holland-Fischer, Michael Schilsky, Santiago Munoz, Tarek Hassanein, William M. Lee

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background/Aims: Soluble CD163 (sCD163) is a scavenger receptor shed in serum during inflammatory activation of macrophages. We investigated if sCD163 was increased and predicted outcome in acute liver failure (ALF). Methods: Samples from 100 consecutive patients enrolled in the U.S. ALF Study Group for whom sera were available were collected on days 1 and 3, and clinical data were obtained prospectively. sCD163 levels were determined by ELISA. Results: The median level of sCD163 was significantly increased in ALF (21.1 mg/l (range 3.6-74.9)) as compared to healthy controls (2.3 mg/l (0.65-5.6), p < 0.0001) and patients with stable liver cirrhosis (9.8 mg/l (3.6-16.9), p = 0.0002). sCD163 on day 1 correlated significantly with ALT, AST, bilirubin, and creatinine. sCD163 concentrations on day 3 were elevated in patients with fatal outcome of disease compared to spontaneous survivors, 29.0 mg/l (7.2-54.0) vs. 14.6 mg/l (3.5-67.2), respectively (p = 0.0025). Patients that were transplanted had intermediate levels. Sensitivity and specificity at a cut-off level of 26 mg/l was 62% and 81%, respectively. Conclusions: Activated macrophages are involved in ALF resulting in a 10-fold increase in sCD163. A high level (>26 mg/l) of sCD163 was significantly correlated with fatal outcome and might be used with other parameters to determine prognosis.

Original languageEnglish (US)
Pages (from-to)671-676
Number of pages6
JournalJournal of Hepatology
Volume47
Issue number5
DOIs
StatePublished - Nov 2007

Fingerprint

Acute Liver Failure
Macrophages
Mortality
Scavenger Receptors
Fatal Outcome
Macrophage Activation
Serum
Enzyme-Linked Immunosorbent Assay

Keywords

  • Acute liver failure
  • Anti-inflammatory markers
  • Prognostic score

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Møller, H. J., Grønbæk, H., Schiødt, F. V., Holland-Fischer, P., Schilsky, M., Munoz, S., ... Lee, W. M. (2007). Soluble CD163 from activated macrophages predicts mortality in acute liver failure. Journal of Hepatology, 47(5), 671-676. https://doi.org/10.1016/j.jhep.2007.05.014

Soluble CD163 from activated macrophages predicts mortality in acute liver failure. / Møller, Holger Jon; Grønbæk, Henning; Schiødt, Frank V.; Holland-Fischer, Peter; Schilsky, Michael; Munoz, Santiago; Hassanein, Tarek; Lee, William M.

In: Journal of Hepatology, Vol. 47, No. 5, 11.2007, p. 671-676.

Research output: Contribution to journalArticle

Møller, HJ, Grønbæk, H, Schiødt, FV, Holland-Fischer, P, Schilsky, M, Munoz, S, Hassanein, T & Lee, WM 2007, 'Soluble CD163 from activated macrophages predicts mortality in acute liver failure', Journal of Hepatology, vol. 47, no. 5, pp. 671-676. https://doi.org/10.1016/j.jhep.2007.05.014
Møller HJ, Grønbæk H, Schiødt FV, Holland-Fischer P, Schilsky M, Munoz S et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. Journal of Hepatology. 2007 Nov;47(5):671-676. https://doi.org/10.1016/j.jhep.2007.05.014
Møller, Holger Jon ; Grønbæk, Henning ; Schiødt, Frank V. ; Holland-Fischer, Peter ; Schilsky, Michael ; Munoz, Santiago ; Hassanein, Tarek ; Lee, William M. / Soluble CD163 from activated macrophages predicts mortality in acute liver failure. In: Journal of Hepatology. 2007 ; Vol. 47, No. 5. pp. 671-676.
@article{65d5474040054b2f91c4e026f5c9e8f7,
title = "Soluble CD163 from activated macrophages predicts mortality in acute liver failure",
abstract = "Background/Aims: Soluble CD163 (sCD163) is a scavenger receptor shed in serum during inflammatory activation of macrophages. We investigated if sCD163 was increased and predicted outcome in acute liver failure (ALF). Methods: Samples from 100 consecutive patients enrolled in the U.S. ALF Study Group for whom sera were available were collected on days 1 and 3, and clinical data were obtained prospectively. sCD163 levels were determined by ELISA. Results: The median level of sCD163 was significantly increased in ALF (21.1 mg/l (range 3.6-74.9)) as compared to healthy controls (2.3 mg/l (0.65-5.6), p < 0.0001) and patients with stable liver cirrhosis (9.8 mg/l (3.6-16.9), p = 0.0002). sCD163 on day 1 correlated significantly with ALT, AST, bilirubin, and creatinine. sCD163 concentrations on day 3 were elevated in patients with fatal outcome of disease compared to spontaneous survivors, 29.0 mg/l (7.2-54.0) vs. 14.6 mg/l (3.5-67.2), respectively (p = 0.0025). Patients that were transplanted had intermediate levels. Sensitivity and specificity at a cut-off level of 26 mg/l was 62{\%} and 81{\%}, respectively. Conclusions: Activated macrophages are involved in ALF resulting in a 10-fold increase in sCD163. A high level (>26 mg/l) of sCD163 was significantly correlated with fatal outcome and might be used with other parameters to determine prognosis.",
keywords = "Acute liver failure, Anti-inflammatory markers, Prognostic score",
author = "M{\o}ller, {Holger Jon} and Henning Gr{\o}nb{\ae}k and Schi{\o}dt, {Frank V.} and Peter Holland-Fischer and Michael Schilsky and Santiago Munoz and Tarek Hassanein and Lee, {William M.}",
year = "2007",
month = "11",
doi = "10.1016/j.jhep.2007.05.014",
language = "English (US)",
volume = "47",
pages = "671--676",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Soluble CD163 from activated macrophages predicts mortality in acute liver failure

AU - Møller, Holger Jon

AU - Grønbæk, Henning

AU - Schiødt, Frank V.

AU - Holland-Fischer, Peter

AU - Schilsky, Michael

AU - Munoz, Santiago

AU - Hassanein, Tarek

AU - Lee, William M.

PY - 2007/11

Y1 - 2007/11

N2 - Background/Aims: Soluble CD163 (sCD163) is a scavenger receptor shed in serum during inflammatory activation of macrophages. We investigated if sCD163 was increased and predicted outcome in acute liver failure (ALF). Methods: Samples from 100 consecutive patients enrolled in the U.S. ALF Study Group for whom sera were available were collected on days 1 and 3, and clinical data were obtained prospectively. sCD163 levels were determined by ELISA. Results: The median level of sCD163 was significantly increased in ALF (21.1 mg/l (range 3.6-74.9)) as compared to healthy controls (2.3 mg/l (0.65-5.6), p < 0.0001) and patients with stable liver cirrhosis (9.8 mg/l (3.6-16.9), p = 0.0002). sCD163 on day 1 correlated significantly with ALT, AST, bilirubin, and creatinine. sCD163 concentrations on day 3 were elevated in patients with fatal outcome of disease compared to spontaneous survivors, 29.0 mg/l (7.2-54.0) vs. 14.6 mg/l (3.5-67.2), respectively (p = 0.0025). Patients that were transplanted had intermediate levels. Sensitivity and specificity at a cut-off level of 26 mg/l was 62% and 81%, respectively. Conclusions: Activated macrophages are involved in ALF resulting in a 10-fold increase in sCD163. A high level (>26 mg/l) of sCD163 was significantly correlated with fatal outcome and might be used with other parameters to determine prognosis.

AB - Background/Aims: Soluble CD163 (sCD163) is a scavenger receptor shed in serum during inflammatory activation of macrophages. We investigated if sCD163 was increased and predicted outcome in acute liver failure (ALF). Methods: Samples from 100 consecutive patients enrolled in the U.S. ALF Study Group for whom sera were available were collected on days 1 and 3, and clinical data were obtained prospectively. sCD163 levels were determined by ELISA. Results: The median level of sCD163 was significantly increased in ALF (21.1 mg/l (range 3.6-74.9)) as compared to healthy controls (2.3 mg/l (0.65-5.6), p < 0.0001) and patients with stable liver cirrhosis (9.8 mg/l (3.6-16.9), p = 0.0002). sCD163 on day 1 correlated significantly with ALT, AST, bilirubin, and creatinine. sCD163 concentrations on day 3 were elevated in patients with fatal outcome of disease compared to spontaneous survivors, 29.0 mg/l (7.2-54.0) vs. 14.6 mg/l (3.5-67.2), respectively (p = 0.0025). Patients that were transplanted had intermediate levels. Sensitivity and specificity at a cut-off level of 26 mg/l was 62% and 81%, respectively. Conclusions: Activated macrophages are involved in ALF resulting in a 10-fold increase in sCD163. A high level (>26 mg/l) of sCD163 was significantly correlated with fatal outcome and might be used with other parameters to determine prognosis.

KW - Acute liver failure

KW - Anti-inflammatory markers

KW - Prognostic score

UR - http://www.scopus.com/inward/record.url?scp=34848840320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848840320&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2007.05.014

DO - 10.1016/j.jhep.2007.05.014

M3 - Article

VL - 47

SP - 671

EP - 676

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -